J. Downs

Management of Retroperitoneal Sarcomas

D. Gyorki, M. Wilkinson, J. Downs, 2020 .

A survey of surgical management of the sentinel node positive melanoma patient in the post‐MSLT2 era

A. Spillane, M. Henderson, D. Gyorki, 2021, Journal of surgical oncology.

Active surveillance of patients who have sentinel node positive melanoma: An international, multi‐institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT‐2)

James X. Sun, Lesly A. Dossett, V. Sondak, 2021, Cancer.

An evidence-based approach to positive sentinel node disease: should we ever do a completion node dissection?

D. Gyorki, J. Downs, 2019, Melanoma management.

Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection

James X. Sun, Lesly A. Dossett, T. Hieken, 2022, Journal for ImmunoTherapy of Cancer.

Providing cancer surgery in the COVID‐19 crisis

D. Gyorki, D. Speakman, M. Wilkinson, 2020, The British journal of surgery.

International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node-Positive Melanoma at Major Referral Centers

James X. Sun, Lesly A. Dossett, V. Sondak, 2022, Annals of surgery.